BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

Completed

Conditions: Prostate Cancer

First Posted Date: 2009-09-25

Last Posted Date: 2016-02-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00984919

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: DHEA
Procedure: Surgical resection

First Posted Date: 2009-09-04

Last Posted Date: 2019-09-17

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00972023

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

Phase 1

Withdrawn

Conditions: Colorectal Cancer

First Posted Date: 2009-08-17

Last Posted Date: 2013-04-16

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00960427

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Phase 2

Terminated

Conditions: Precancerous Condition
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Dietary Supplement: defined green tea catechin extract
Genetic: gene expression analysis
Genetic: protein analysis
Other: laboratory biomarker analysis

First Posted Date: 2009-07-20

Last Posted Date: 2015-03-27

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00942422

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2009-07-14

Last Posted Date: 2013-09-23

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00938626

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Not Applicable

Recruiting

Conditions: Leukemia
Lymphoproliferative Disorder
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Myelodysplastic/Myeloproliferative Neoplasms
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Device: 3'-deoxy-3'-[18F]fluorothymidine

First Posted Date: 2009-07-08

Last Posted Date: 2024-06-28

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00935090

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx

Phase 1

Completed

Conditions: Perioperative/Postoperative Complications
Head and Neck Cancer
Precancerous Condition

Interventions: Procedure: assessment of therapy complications
Procedure: diagnostic endoscopic surgery
Procedure: quality-of-life assessment
Procedure: therapeutic conventional surgery
Procedure: therapeutic endoscopic surgery
Procedure: transoral robotic surgery
Procedure: video-assisted surgery

First Posted Date: 2009-06-11

Last Posted Date: 2014-05-09

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00918762

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

Not Applicable

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Procedure: pulmonary function testing

First Posted Date: 2009-06-04

Last Posted Date: 2021-03-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00914147

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

Phase 1

Completed

Conditions: Pulmonary Nodule

Interventions: Drug: dexamethasone
Procedure: PET/Computed Tomography (CT)
Radiation: fludeoxyglucose (18F)

First Posted Date: 2009-05-21

Last Posted Date: 2015-04-07

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00906503

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Sinai-Grace Hospital, Detroit, Michigan, United States

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2009-05-18

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00903214

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy